Acute Myeloid Leukemia Coverage From Every Angle

Published Medical Literature

Therapeutic Update in AML: Genomic Assessment Is Key
Lipid Core Nanoparticles Plus Etoposide With Transplantation for AML
Combination Therapy Under Study in Resistant FLT3-ITD–Mutated AML
Sorafenib Maintenance After Stem Cell Transplantation in FLT3-ITD AML
Update on Total-Body Irradiation in Children With de Novo AML
Therapeutic Considerations for Patients With AML Older Than Age 80
Can Dasatinib Overcome Resistance to FLT3 Inhibition in AML?
Can Immunoglobulin Expression Predict Survival in Patients With AML?
Link Between Cognitive Impairment and Outcomes in Older Recipients of Allogeneic HCT?
Low-Dose Cytarabine Plus Glasdegib in AML
Differentiation Syndrome With IDH Inhibitors in Resistant AML: FDA Analysis
Do CSF3R Mutations Affect Prognosis for Children With Favorable-Risk AML?
Secondary AML Risk Factors After Stem Cell Transplantation
Comparing AML Induction Regimens After Failure of Hypomethylating Agents
AML and Checkpoint Inhibitors: Outcomes With Cyclophosphamide After Transplantation
Venetoclax-Based Regimen for Patients With AML Ineligible for Intensive Chemotherapy
Predictors of Outcomes During Induction Chemotherapy for Patients With AML
Rare Case of Dual AML and Multiple Myeloma: Combination Therapy Active for Both
Busulfan Versus Melphalan: Long-Term Outcomes After Transplantation for AML
Long-Term Outcomes for Children With AML: Vietnamese Retrospective Study
Hematopoietic Stem Cell Transplantation for AML: Role of Genetic Mutation
Maintenance Selinexor After Allo-HCT for High-Risk AML
BRIGHT AML 1019 Trial to Study Glasdegib Plus Chemotherapy in Acute Myeloid Leukemia
Preserving Cardiac Function With Dexrazoxane in Pediatric Patients With AML
10-Year Data on Allo-HCT: Reduced-Intensity Versus Standard Conditioning Regimens
Fine-Tuning Cytarabine Treatment in Children With AML to Improve Outcomes
Feasibility of Outpatient Intensive Induction Chemotherapy for AML
Can Adding Venetoclax to FLAG-IDA Regimen Improve Outcomes in Patients With AML?
New Role Explored for Lenalidomide: With Chemotherapy for Older Patients With AML
Novel Combination of Lithium and Tretinoin for Treatment-Resistant AML
Additional Venetoclax-Inclusive Drug Combinations for Elderly Patients With AML
Aspacytarabine for Patients With AML Who Are Unfit for Standard Chemotherapy
Conditioning Intensity Before Transplantation May Affect Outcomes in AML
Sorafenib in FLT3/ITD-Positive AML: Impact of Co-occurring Mutations
Venetoclax-Based Regimen for Pediatric Patients With Resistant AML
Concordant AML in Twin Sisters: Impact of Prepubertal Cancer Treatment
Comparison of Conditioning Regimens Before Transplantation in Older Patients With AML
Can Early Cytogenetic Testing Improve Outcomes With HCT in AML?
Role of Isocitrate Dehydrogenase Inhibitors in AML Treatment
ADMIRAL Trial: Genetic Mutations in Patients With Resistant AML
Using Targeted Therapy in Older Patients With AML
Expression of Transcription Factors in Newly Diagnosed Acute Myeloid Leukemia
Epigenetic Alteration of HIST1 in Acute Myeloid Leukemia With NPM1 Mutation
Nivolumab Plus Front-Line Chemotherapy in Newly Diagnosed AML
How Does Gilteritinib Compare With Chemotherapy for FLT3 -Mutated AML?

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.